Novo Nordisk, the maker of the wildly popular obesity drug Wegovy, said Thursday it would temporarily limit some “starter” doses for new patients in the United States to ensure a steady supply for people already on the medication.
The company will cut the supply of lower-strength doses available that new patients start with, it said.
The announcement from Novo is the latest demonstration of the surging interest for the weight-loss medication and the company’s struggles to meet that demand. Some patients have resorted to trying to find the active ingredients themselves.
About the Author Reprints
